272 related articles for article (PubMed ID: 37909018)
1. Exploring the therapeutic potential of targeting polycomb repressive complex 2 in lung cancer.
Gao M; Li Y; Cao P; Liu H; Chen J; Kang S
Front Oncol; 2023; 13():1216289. PubMed ID: 37909018
[TBL] [Abstract][Full Text] [Related]
2. EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex.
Hsu JH; Rasmusson T; Robinson J; Pachl F; Read J; Kawatkar S; O' Donovan DH; Bagal S; Code E; Rawlins P; Argyrou A; Tomlinson R; Gao N; Zhu X; Chiarparin E; Jacques K; Shen M; Woods H; Bednarski E; Wilson DM; Drew L; Castaldi MP; Fawell S; Bloecher A
Cell Chem Biol; 2020 Jan; 27(1):41-46.e17. PubMed ID: 31786184
[TBL] [Abstract][Full Text] [Related]
3. EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.
Wassef M; Luscan A; Aflaki S; Zielinski D; Jansen PWTC; Baymaz HI; Battistella A; Kersouani C; Servant N; Wallace MR; Romero P; Kosmider O; Just PA; Hivelin M; Jacques S; Vincent-Salomon A; Vermeulen M; Vidaud M; Pasmant E; Margueron R
Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6075-6080. PubMed ID: 30867289
[TBL] [Abstract][Full Text] [Related]
4. Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs.
Zhao Y; Guan YY; Zhao F; Yu T; Zhang SJ; Zhang YZ; Duan YC; Zhou XL
Eur J Med Chem; 2022 Mar; 231():114144. PubMed ID: 35093670
[TBL] [Abstract][Full Text] [Related]
5. Clinical Correlations of Polycomb Repressive Complex 2 in Different Tumor Types.
Erokhin M; Chetverina O; Győrffy B; Tatarskiy VV; Mogila V; Shtil AA; Roninson IB; Moreaux J; Georgiev P; Cavalli G; Chetverina D
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34202528
[TBL] [Abstract][Full Text] [Related]
6. Polycomb repressive complex 2 is required for MLL-AF9 leukemia.
Neff T; Sinha AU; Kluk MJ; Zhu N; Khattab MH; Stein L; Xie H; Orkin SH; Armstrong SA
Proc Natl Acad Sci U S A; 2012 Mar; 109(13):5028-33. PubMed ID: 22396593
[TBL] [Abstract][Full Text] [Related]
7. Regulatory interactions between RNA and polycomb repressive complex 2.
Cifuentes-Rojas C; Hernandez AJ; Sarma K; Lee JT
Mol Cell; 2014 Jul; 55(2):171-85. PubMed ID: 24882207
[TBL] [Abstract][Full Text] [Related]
8. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
Xu B; Konze KD; Jin J; Wang GG
Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
[TBL] [Abstract][Full Text] [Related]
9. PRC2/EED-EZH2 complex is up-regulated in breast cancer lymph node metastasis compared to primary tumor and correlates with tumor proliferation in situ.
Yu H; Simons DL; Segall I; Carcamo-Cavazos V; Schwartz EJ; Yan N; Zuckerman NS; Dirbas FM; Johnson DL; Holmes SP; Lee PP
PLoS One; 2012; 7(12):e51239. PubMed ID: 23251464
[TBL] [Abstract][Full Text] [Related]
10. Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer.
Martin MC; Zeng G; Yu J; Schiltz GE
J Med Chem; 2020 Dec; 63(24):15344-15370. PubMed ID: 33283516
[TBL] [Abstract][Full Text] [Related]
11. Mutations and deletions of PRC2 in prostate cancer.
Jain P; Di Croce L
Bioessays; 2016 May; 38(5):446-54. PubMed ID: 27000413
[TBL] [Abstract][Full Text] [Related]
12. A Noncanonical Function of Polycomb Repressive Complexes Promotes Human Cytomegalovirus Lytic DNA Replication and Serves as a Novel Cellular Target for Antiviral Intervention.
Svrlanska A; Reichel A; Schilling EM; Scherer M; Stamminger T; Reuter N
J Virol; 2019 May; 93(9):. PubMed ID: 30814291
[TBL] [Abstract][Full Text] [Related]
13. Embryonic Ectoderm Development (EED) as a Novel Target for Cancer Treatment.
Cook N; Chen J; Zhou J; Wu D
Curr Top Med Chem; 2021; 21(31):2771-2777. PubMed ID: 34544341
[TBL] [Abstract][Full Text] [Related]
14. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
[TBL] [Abstract][Full Text] [Related]
15. Non-canonical functions of EZH2 in cancer.
Zimmerman SM; Lin PN; Souroullas GP
Front Oncol; 2023; 13():1233953. PubMed ID: 37664059
[TBL] [Abstract][Full Text] [Related]
16. Polycomb repressive complex 2 regulates normal development of the mouse heart.
He A; Ma Q; Cao J; von Gise A; Zhou P; Xie H; Zhang B; Hsing M; Christodoulou DC; Cahan P; Daley GQ; Kong SW; Orkin SH; Seidman CE; Seidman JG; Pu WT
Circ Res; 2012 Feb; 110(3):406-15. PubMed ID: 22158708
[TBL] [Abstract][Full Text] [Related]
17. Polycomb repressive 2 complex-Molecular mechanisms of function.
Kouznetsova VL; Tchekanov A; Li X; Yan X; Tsigelny IF
Protein Sci; 2019 Aug; 28(8):1387-1399. PubMed ID: 31095801
[TBL] [Abstract][Full Text] [Related]
18. Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer.
Chen H; Gao S; Li J; Liu D; Sheng C; Yao C; Jiang W; Wu J; Chen S; Huang W
Oncotarget; 2015 May; 6(15):13049-59. PubMed ID: 25944687
[TBL] [Abstract][Full Text] [Related]
19. PRC2 disruption in cerebellar progenitors produces cerebellar hypoplasia and aberrant myoid differentiation without blocking medulloblastoma growth.
Cleveland AH; Malawsky D; Churiwal M; Rodriguez C; Reed F; Schniederjan M; Velazquez Vega JE; Davis I; Gershon TR
Acta Neuropathol Commun; 2023 Jan; 11(1):8. PubMed ID: 36635771
[TBL] [Abstract][Full Text] [Related]
20. Binding Modes of Small-Molecule Inhibitors to the EED Pocket of PRC2.
Huang D; Tian S; Qi Y; Zhang JZH
Chemphyschem; 2020 Feb; 21(3):263-271. PubMed ID: 31816138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
